Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Multi-Center Phase I/II Study to Evaluate Efficacy and Safety of BGB-290 in Chinese Subjects With Advanced Ovarian Cancer, Fallopian Cancer, and Primary Peritoneal Cancer or Advanced Triple Negative Breast Cancer

NCT03333915 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT03333915
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03333915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Multi-Center Phase I/II Study to Evaluate Efficacy and Safety of BGB-290 in Chinese Subjects With Advanced Ovarian Cancer, Fallopian Cancer, and Primary Peritoneal Cancer or Advanced Triple Negative Breast Cancer
Lead sponsor
BeiGene
Phase
Phase 1/2
Overall status
Completed
Start date
December 21, 2016
Completion date
August 11, 2021
Enrollment
128 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced high-grade ovarian cancer, triple negative breast cancer